Spontaneous regression of breast cancer with immune response: a case report

Masahiro Ohara1*, Yumiko Koi1,4, Tatsunari Sasada1, Keiko Kajitani1, Seishi Mizuno2, Ai Takata2, Atsuko Okamoto2, Ikuko Nagata2, Mie Sumita2, Kaita Imachi2, Mayumi Watanabe2, Yutaka Daimaru2 and Shingo Kawamura3

Abstract
Background: Spontaneous regression (SR) is a rare phenomenon in which a cancer disappears or remits without treatment. We report a case of breast cancer that showed spontaneous tumor regression in the surgical specimen after core needle biopsy.

Case presentation: A 59-year-old woman came to our hospital complaining of a painful lump in the right breast. In the upper-outer quadrant of the right breast, a tumor with an unclear boundary, 30 mm in diameter, was palpable. In pathological findings from needle biopsy, the tumor was diagnosed as solid-type invasive ductal breast carcinoma. Partial coagulation necrosis was generated in estrogen receptor-negative, HER2-negative, and AE1/AE3-positive ductal carcinoma without infiltration of lymphocytes. Surgery for right breast cancer was then performed. Histological examination of the surgical specimen revealed the tumor was invasive ductal carcinoma with lymphocyte infiltration, coagulation necrosis, and fibrous tissue with hemosiderin. The tumor formed a solid nest, 3 mm in diameter, suggesting the possibility of SR.

Conclusions: Immune responses, infection, hormones, surgical stress, and ischemia have been reported as mechanisms of SR. The findings in this case strongly suggest that SR of breast cancer is associated with anti-tumor immune responses.

Keywords: Breast cancer, Spontaneous regression, Immunogenic cell death

Background
Spontaneous regression (SR) of cancer is a rare but well-documented biological phenomenon. SR is defined as “the partial or complete disappearance of a tumor in the absence of any treatment capable of regression” [1, 2]. Breast cancer regression was reported in 43/741 cases of spontaneously regressing cancers compiled and summarized by Challis and Stam in a review of the period from 1900 to 1987 [3], and few additional reports have been published since then [4–9]. Various mechanisms are considered to be associated with this phenomenon, including immune mediation, tumor inhibition by growth factors and/or cytokines, induction of differentiation, hormonal mediation, and tumor necrosis.

Spontaneously induced T-cell-mediated immunological responses have recently gained attention in multidisciplinary cancer treatment, since more than 30% of durable clinical responses including complete response are observed just with administration of antibody to block the PD-1/PD-L1 inhibitory immunological checkpoint signal in various cancer patients [10, 11]. Spontaneously induced immunological responses could thus also be an important mechanism in the SR of cancer.

We report herein a case of SR of breast cancer with induced immune responses. Immunohistochemically, we confirmed that partial coagulation necrosis was generated in estrogen receptor-negative, HER2-negative, and AE1/AE3-positive ductal carcinoma without infiltration of lymphocytes on preoperative pathological findings.
Postoperative histopathological findings consequently showed that most tumor cells had been replaced by granulation tissue and residual ductal carcinoma had been driven into a smaller area by the infiltration of lymphocytes, suggesting that the SR of this breast cancer could be due to anti-tumor immune responses induced by unexplained inflammation.

**Case presentation**

A 59-year-old woman came to our hospital with a chief complaint of a painful lump in the right breast. She regularly visited her primary doctor for type 2 diabetes, hypertension, and hyperlipidemia. She was treated with metformin, olmesartan medoxomil/azelnidipine, and pravastatin for less than 5 years. She had no family history associated with breast cancer. Reviewing her past history, she had received total hysterectomy at age of 47 for a uterine leiomyoma. A tumor with an unclear boundary was palpable in the upper-outer region of the right breast, about 30 mm in diameter along the major axis. Mammography revealed a mass with a clear boundary, 19 × 18 mm in size, in the middle outer portion of the right breast (Fig. 1a, b). Ultrasonography revealed a smooth, round mass measuring 20 × 18 × 18 mm in size, in the upper-outer quadrant of the right breast. Subcutaneous fat tissue around the tumor appeared as a highly echogenic, edematous region (Fig. 1c). In pathological findings from needle biopsy, the tumor was diagnosed as solid-type invasive ductal breast carcinoma. Partial coagulation necrosis was generated in estrogen receptor-negative, HER2-negative, and AE1/ AE3-positive ductal carcinoma without infiltration of lymphocytes (Fig. 2a–j, 3a–e). Thirteen days after core needle biopsy, magnetic resonance imaging (MRI) was performed. MRI showed a smooth, round mass measuring 20 × 16 × 15 mm in size with slight hyperintensity on T1-weighted MRI and with high intensity on T2-weighted MRI. Only the marginal region of the tumor was enhanced (Fig. 1e–g). Ring-type dedicated breast positron emission tomography showed a ring-shaped fluorodeoxyglucose accumulation in the right breast (Fig. 1h). We performed ultrasonography just before surgery, showing that the tumor remained the same shape as before, although the size had decreased to 12 × 10 × 11 mm and the edema around the tumor had disappeared (Fig. 1d). Right partial breast resection and sentinel lymph node biopsy was performed 53 days after core needle biopsy. On histological examination of the surgical specimen, the tumor was showed lymphocyte infiltration, coagulation necrosis, and fibrous tissue

![Fig. 1 Preoperative imaging findings. a Mediolateral oblique-view mammogram. b Craniocaudal-view mammogram. A mass with a clear boundary is recognized in the right breast. c Ultrasonogram at first visit. A smooth, round mass is apparent in the upper-outer quadrant of the right breast. Subcutaneous fat tissue around the tumor appears as a highly echogenic, edematous layer. d Ultrasonogram just before surgery. Edema around the tumor has disappeared. e T1-weighted magnetic resonance imaging (MRI). f T2-weighted MRI. g MRI with early gadolinium enhancement. A smooth, round mass with slight hyperintensity on T1-weighted MRI and hyperintensity on T2-weighted MRI. Only the marginal region of the tumor appears enhanced. h Ring-type dedicated breast positron emission tomography. A ring-shaped accumulation of 18F-fluorodeoxyglucose is evident in the right breast.](image-url)
spread with hemosiderin deposition. The tumor formed a solid nest, 3 mm in diameter, suggesting the possibility of SR (Fig. 4a–d). A significant aggregation of lymphocytes was observed around tumor cells. These lymphocytes comprised CD3-positive, CD4-positive, or CD8-positive T cells (Fig. 5a–c) accompanied by aggregations of CD20-positive B-cells (Fig. 5d), but few CD56-positive natural killer (NK) cells (Fig. 5e). In addition, residual tumor cells in the surgical specimen did not express PD-L1 (Fig. 5f).

Adjuvant radiation therapy (50 Gy in 25 fractions) to the whole breast was performed. The patient is

Fig. 2 Preoperative pathologic findings. The histopathological findings of the right breast from core needle biopsy (a, f: hematoxylin and eosin (HE) × 40; b, g: HE × 200). Immunohistochemistry study for AE1/AE3, estrogen receptor (ER), and HER2 (c, h: AE1/AE3 × 40; d, i: ER × 40; e, j: HER2 × 40). Small foci of atypical ductal cells are recognized (yellow arrow). Partial coagulation necrosis is generated in estrogen receptor-negative, HER2-negative, and AE1/AE3-positive ductal carcinoma without infiltration of lymphocytes.

Fig. 3 Immunohistochemical staining for core needle biopsy specimens. Immunohistochemistry study for immunological surface markers (a: CD3; b: CD4; c: CD8; d: CD20; e: CD56. All original magnifications are × 200). The necrotic area in needle biopsy did not contain immune cells.
being followed-up closely, with examinations every 3–4 months, and is undergoing regular breast examinations, breast ultrasonography, mammography and tumor marker evaluations (carcinoma antigen 15–3 and carcinomaembryonic antigen). After 16 months of follow-up, we have not observed any signs of cancer relapse, and the patient has remained free of the disease.

Discussion
SR of breast cancer is a rare event that is recognized in the medical literature, but is still an unexpected phenomenon. Due to the rarity of SR, case reports and studies of the reported single cases remain restricted by the lack of sufficient data on a number of biological behaviors and their clinical significance.

Possible mechanisms underlying spontaneous cancer regression include immune system or hormonal mediation, tumor inhibition by growth factors/cytokines, induction of differentiation, elimination of a carcinogen, tumor necrosis, angiogenesis inhibition, psychological factors, apoptosis, and epigenetic mechanisms [1, 2]. This phenomenon has been speculated to be possibly related to trauma or infection [1, 4]. In the current case, the patient could not remember any traumatic or infectious events involving the site. Furthermore, she did not change her pattern of living and her medication regimen was not changed before surgery. Although the patient took metformin and pravastatin for 5 years, the possibility could not be denied that metformin and pravastatin has played an important role in this regression. Retrospective studies have demonstrated that metformin and statin decreased incidence and recurrence rate of breast cancer potentially [12–15]. Pain symptoms at the tumor site and the edema around the tumor on ultrasonography showed the existence of inflammation, irrespective of cause. Preoperative histopathological findings revealed tumor generation and necrosis without infiltration of inflammatory cells at that time.

Immunogenic cell death (ICD), a newly defined form of cell death, may involve recruitment of the host immune system, thereby resulting in immune memory and advantageous systemic effects. ICD of cancer cells can induce effective antitumor immune responses through activation of dendritic cells (DCs) and consequent activation of specific T-cell responses [16, 17]. ICD is defined as several steps resulting in the translocation of calreticulin
to the cell surface (an “eat-me” signal for DCs) and the release of danger signals such as HMGB1 and ATP, which are essential for the promotion of CD8 T-cell anticancer responses [18]. ICD can be induced by chemotherapeutic agents such as anthracyclines and oxaliplatin, or radiotherapy and photodynamic therapy, or some physical therapies [19]. In the present case, surgical specimens showed tumor cells surrounded by abundant lymphocytes, while core needle biopsy specimens had not contained tumor-infiltrating lymphocytes. Unknown ICD-derived anti-tumor immunity was speculated to have caused residual tumor regression.

The roles and subsets of tumor-infiltrating lymphocytes have been discussed in cases involving SR of breast cancer [5, 6]. Both CD4- and CD8-positive subsets of CD3-positive T-cells have been implicated in the genesis of SR [6], although NK cells were suggested in another case [5]. In the present case, the aggregated cells were mainly CD3-, CD8-, or CD4-positive T-cells, while CD56-positive NK cells were not observed, consistent with a previous report [6]. A few reports have discussed the triggers generating antitumor immunity during spontaneous tumor regression. The initiating event might be related to the trauma from biopsy, as suggested by Maillet et al. [5]. To the best of our knowledge, this is the first case to suggest that ICD of tumor cells could induce anti-tumor immunity resulting in SR of breast cancer based on pre- and postoperative pathological findings. Furthermore, the immune response could potentially have continued and the patient might have achieved complete remission without surgery, as the final tumor cells did not express PD-L1 despite the infiltration of abundant lymphocytes.

**Conclusions**

Our case distinctly indicates that SR of breast cancer is associated with ICD. One limitation of our study was that we could not show concrete reasons and molecular markers for ICD. Recognizing the presence of SR and ICD of breast cancer is important, and a more detailed understanding of the mechanisms underlying SR and ICD would provide significant implications for cancer prevention and therapeutics.

**Abbreviations**

SR: Spontaneous regression; ICD: Immunogenic cell death; DCs: Dendritic cells; MRI: Magnetic resonance imaging; HE: Hematoxylin and eosin.
Acknowledgements
We would like to thank Forte (https://www.forte-science.co.jp/) for English language editing.

Authors’ contributions
SK provided the clinical data included in the text. MO wrote the manuscript draft and critically revised the manuscript for important intellectual content. YK, TS, and KK contributed to the conception of the work and interpreted and revised the results of PET-CT, MRI, mammograms, and ultrasonograms included in this study. SM, AT, AO, IN, MS, KI, and MW collected and analyzed the histopathological data. YD diagnosed the disease pathologically. All authors read and approved the final manuscript.

Funding
No commercial, public, or nonprofit organizations financially supported this research.

Availability of data and materials
All data analyzed during this study are included within the manuscript. The datasets used and/or analyzed during this study are available from the first author on reasonable request.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication
Written consent to publish this information was obtained from the patient.

Consent for publication
All authors declare that they have no competing interests.

Author details
1 Department of Breast Surgery, Hiroshima General Hospital, 1-3-3 Jigozen, Hatsukaichi, Hiroshima 738-8503, Japan. 2 Section of Pathological Research and Laboratory, Hiroshima General Hospital, 1-3-3 Jigozen, Hatsukaichi, Hiroshima 738-8503, Japan. 3 Suzumine Imanaka Clinic, 4-2-31, Inokuchi, Nishi-ku, Hatsukaichi, Hiroshima 733-0842, Japan. 4 Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.

Received: 18 September 2020   Accepted: 26 December 2020
Published online: 06 January 2021

References
1. Cole WH. Spontaneous regression of cancer and the importance of finding its cause. Natl Cancer Inst Monogr. 1976;44:5–9.
2. Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201–9.
3. Challis GB, Stann HJ. The spontaneous regression of cancer: a review of cases from 1900 to 1987. Acta Oncol. 1990;29:545–50.
4. Dussan C, Zubor P, Fernandez M, Yabar A, Szunyogh N, Visnovsky J. Spontaneous regression of a breast carcinoma: a case report. Gynecol Obstet Invest. 2008;65:206–11.
5. Macche AG, Jekunen A, Risspanen P, Virkkunen P, Halavaara J, Turunen JP. Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancer. Eur J Cancer. 1994;30A:1642–6.
6. Tokunaga E, Okano S, Nakashima Y, Yamashita N, Tanaka K, Akiyoshi S, et al. Spontaneous regression of breast cancer with axillary lymph node metastasis: a case report and review of literature. Int J Clin Exp Pathol. 2014;7:4371–80.
7. Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, et al. Spontaneous regression of breast cancer after biopsy. About two cases Gynecol Obstet Fertil. 2014;42:269–72.
8. Ito E, Nakano S, Otsuka M, Mibu A, Karikomi M, Oinuma T, et al. Spontaneous breast cancer remission: a case report. Int J Surg Case Rep. 2016;25:132–6.
9. Cserni G, Serfozo O, Ambrozay E, Markó L, Krenács L. Spontaneous pathological complete regression of high-grade triple-negative breast cancer with axillary metastasis. Pol J Pathol. 2019;70:139–43.
10. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.
11. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.
12. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012;135:639–46.
13. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care. 2013;36:3018–26.
14. Lv H, Shi D, Fei M, Chen Y, Xie F, Wang Z, et al. Association between statin use and prognosis of breast cancer: a meta-analysis of cohort studies. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.556243 (eCollection 2020).
15. Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer (Dove Med Press). 2017;9:559–65.
16. Krysko DV, Garg AD, Kaczmarék A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–75.
17. Spisak R, Dhadapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle. 2007;6:1962–5.
18. Kromer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72.
19. Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23:4854–65.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.